Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Radius has acquired the exclusive worldwide rights to develop, manufacture and distribute Ipsen's molecule BA058 as a potential treatment for osteoporosis.
Subscribe to our email newsletter
Radius has also acquired the rights to the analogs of the molecule, along with rights to several Ipsen novel formulation technologies.
The license is on a worldwide basis with the exception of Japan, where Ipsen previously granted an exclusive license for BA058 to the Japanese group, Teijin. Radius will pay Ipsen upfront and milestone payments linked to development and registration of the product, as well as royalties calculated on a pro rata sales basis.
BA058 is an analog of PTHrP (parathyroid hormone-related protein) and is currently in phase I clinical trials for the treatment of osteoporosis. There is increasing evidence that human PTHrP is a critical cytokine in the regulation of bone metabolism and bone mass.
“BA058 has the potential to become an important new anabolic therapy for osteoporosis. We are developing it to build new bone in patients with significant bone loss to reduce the risk of fractures,” said Dr Richard Lyttle, president and CEO of Radius.